Researchers at Brigham and Women's Hospital have developed a means of improving prognosis methods and predicting how long patients with MDS will live after diagnosis by identifying certain gene mutations in their abnormal bone marrow For patients with myelodysplastic syndromes (MDS), choosing the appropriate treatment depends heavily on the prognosis. Those patients at the highest risk of dying from their disease are typically offered the most aggressive therapies, while patients at lower risk could live several years with MDS, needing only supportive care or other relatively...
redOrbit 2011-07-01
